Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this episode of the podcast discusses the future of cancer treatment and the importance of developing more precise and accessible treatment alternatives for patients with solid cancers.
Key discussion points from the podcast:
Melbourne, Australia, 17 October 2023 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately. He holds extensive experience from a diverse scientific background encompassing both academic research and […]
Cartherics’ Dr Ian Nisbet (Chief Operating Officer) and Kathy Skoff (Clinical Trials Manager) recently attended an ovarian cancer symposium in Sydney, organised by Ovarian Cancer Australia and sponsored by AstraZeneca and GSK. It was an excellent event, with an exceptional panel of speakers who provided overviews of the different types of ovarian cancer along with […]
by Richard Boyd and Aleta Pupovac
A question which has long baffled scientists, frustrated clinicians and devastated patients is why does the immune system so effectively defend against infections but so poorly deal with cancer? What lessons can be learnt?
Thanks to a molecular biology-led revolution in immunotherapy, we are now beginning to strategically apply the immune […]
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.
Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.
The forum […]
The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum was held at Monash University’s Suzhou campus in China last week and was also available for online attendance.
The forum’s program was designed to promote connections and enhance collaborations between the Australian and Chinese research and […]
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]
Cartherics is hosting a White Shirt Day lunch on 8th May to help raise funds and awareness for ovarian cancer. The White Shirt Campaign officially launches on April 11th and culminates on White Shirt Day (8 May) – World Ovarian Cancer Day.
The campaign is a 15-year partnership between the Ovarian Cancer Research Foundation (OCRF) […]
Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.
Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
